DB 002
Alternative Names: DB-002Latest Information Update: 20 Apr 2021
At a glance
- Originator DotBio
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 05 Apr 2021 DB 002 is available for licensing as of 05 Apr 2021. https://www.dotbio.com/en/pipeline (DotBio pipeline, April 2021)
- 01 Apr 2021 Early research in Solid tumours in Singapore (Parenteral) (DotBio pipeline, April 2021)